Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) will host an investor webinar on March 18 at 3:30 pm ET to discuss follow-up data from its first-in-human Targeted Hyperthermia Therapy (THT) study.
In 10 late-stage melanoma patients, THT generated immune responses in 8/10 tumors, with 6/10 complete responses. Data will include evidence of an abscopal effect in untreated tumors.
CEO David Regan and CMO Dr. Carman Giacomantonio will join Dr. Carlos Rojas to present findings and answer questions.